company background image
TMDX logo

TransMedics Group NasdaqGM:TMDX Stock Report

Last Price

US$63.90

Market Cap

US$2.1b

7D

-2.7%

1Y

-20.8%

Updated

24 Dec, 2024

Data

Company Financials +

TransMedics Group, Inc.

NasdaqGM:TMDX Stock Report

Market Cap: US$2.1b

TMDX Stock Overview

A commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. More details

TMDX fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance2/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

TransMedics Group, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for TransMedics Group
Historical stock prices
Current Share PriceUS$63.90
52 Week HighUS$177.37
52 Week LowUS$59.72
Beta2.06
1 Month Change-15.97%
3 Month Change-56.91%
1 Year Change-20.81%
3 Year Change224.04%
5 Year Change236.14%
Change since IPO185.78%

Recent News & Updates

Recent updates

TransMedics Faces Market Turbulence As Growth Engines Stutter

Dec 04

These 4 Measures Indicate That TransMedics Group (NASDAQ:TMDX) Is Using Debt Reasonably Well

Nov 20
These 4 Measures Indicate That TransMedics Group (NASDAQ:TMDX) Is Using Debt Reasonably Well

TransMedics: Long-Term Thesis Hasn't Changed At All

Nov 19

TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)

Nov 12

What You Can Learn From TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S After Its 44% Share Price Crash

Oct 30
What You Can Learn From TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S After Its 44% Share Price Crash

TransMedics: Mistakes Have Been Made, Here's My Updated Outlook

Oct 29

TransMedics' Organ Care: Critical Innovation With Lofty Expectations

Oct 23

TransMedics Group: This Could Be One Of The Biggest Moats In A Decade

Oct 16

Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)

Sep 18
Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)

TransMedics: Take Profits While The Valuation Is Sky High

Sep 18

TransMedics: Wide Moat Player At A Lower Valuation Than Peers

Sep 10

TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 25% Share Price Bounce

Aug 28
TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 25% Share Price Bounce

TransMedics: Heart And Lungs Will Drive The Next Leg Higher

Aug 19

Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts

Aug 06
Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts

TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy

Aug 04

TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 02
TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next

TransMedics Group Stock: Too Far, Too Fast

Jul 08

TransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is Pricey

Jun 17

TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger

Jun 10
TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger

TransMedics: Transportation Supporting Growth

May 21

TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)

May 06

TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Apr 24
TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

TransMedics Group: Founder Led Company With Solid Potential

Apr 19

Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?

Apr 11
Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?

TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway

Mar 19

TransMedics Group: Huge Opportunity In Organ Transplants

Mar 12

TransMedics: A Very Expensive Growth Stock

Feb 07

With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For

Jan 23
With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For

Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)

Jan 02
Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)

Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?

Nov 05
Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?

This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year

Aug 06
This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year

TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?

Aug 02
TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?

TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing

Jun 29
TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing

Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts

May 06
Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts

Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?

Apr 27
Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?

Estimating The Intrinsic Value Of TransMedics Group, Inc. (NASDAQ:TMDX)

Apr 09
Estimating The Intrinsic Value Of TransMedics Group, Inc. (NASDAQ:TMDX)

Shareholder Returns

TMDXUS Medical EquipmentUS Market
7D-2.7%-1.1%-2.2%
1Y-20.8%10.1%23.9%

Return vs Industry: TMDX underperformed the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: TMDX underperformed the US Market which returned 23.9% over the past year.

Price Volatility

Is TMDX's price volatile compared to industry and market?
TMDX volatility
TMDX Average Weekly Movement12.2%
Medical Equipment Industry Average Movement7.8%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: TMDX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: TMDX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1998584Waleed Hassaneinwww.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers.

TransMedics Group, Inc. Fundamentals Summary

How do TransMedics Group's earnings and revenue compare to its market cap?
TMDX fundamental statistics
Market capUS$2.14b
Earnings (TTM)US$32.64m
Revenue (TTM)US$401.09m

65.7x

P/E Ratio

5.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TMDX income statement (TTM)
RevenueUS$401.09m
Cost of RevenueUS$163.10m
Gross ProfitUS$237.99m
Other ExpensesUS$205.35m
EarningsUS$32.64m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.97
Gross Margin59.34%
Net Profit Margin8.14%
Debt/Equity Ratio242.2%

How did TMDX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 21:43
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TransMedics Group, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David RescottBaird
William PlovanicCanaccord Genuity
Kristen StewartCL King & Associates, Inc.